Transcriptional splice variants of CD40 and its prognostic value in breast cancer
Transcriptional splice variants of CD40 and its prognostic value in breast cancer
CD40 is an important tumor necrosis factor receptor (TNFR) family protein for the development of antitumor responseagainst cancer cells, apart from its role in the regulation of the immune system as a costimulatory molecule. It is broadly expressed onthe surface of immune cells and in diverse cancer types, including breast cancer. Here, we analyzed both CD40/CD40 ligand expressionin breast cancer cells and tissues using public data sets and overall survival analysis in ungrouped breast cancer patients, as well asin the triple-negative breast cancer subtype. We detected CD40 gene expression along with its 3 different splice variants (variants1–3), predominantly in the triple-negative subgroup of breast cancer cell lines. The results of the overall survival analysis showed thathigh CD40 gene expression, particularly in the triple-negative subgroup of breast cancer patients, is associated with better survival. Inaddition to the transcriptional levels of CD40 splice variants, investigation of protein levels of these variants will allow the categorizationof breast cancer cells and reveal their potential as an immunotherapeutic target.
___
- Ara A, Ahmed KA, Xiang J (2018). Multiple effects of CD40–CD40L
axis in immunity against infection and cancer. ImmunoTargets
and Therapy 7: 55-61.
- Argiriadi MA, Benatuil L, Dubrovska I, Egan DA, Gao L et al. (2019).
CD40/anti-CD40 antibody complexes which illustrate agonist
and antagonist structural switches. BMC Molecular and Cell
Biology 20: 29.
- Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin
AA et al. (2012). The Cancer Cell Line Encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature 483:
603-607.
- Baxendale AJ, Dawson CW, Stewart SE, Mudaliar V, Reynolds G et al.
(2005). Constitutive activation of the CD40 pathway promotes
cell transformation and neoplastic growth. Oncogene 24: 7913-
7923.
- Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J,
Valsesia-Wittmann S et al. (2019). Cold tumors: a therapeutic
challenge for ımmunotherapy. Frontiers in Immunology 10:
168.
- Dong L, Wang S, Chen M, Li H, Bi W (2008). The activation of
macrophage and upregulation of CD40 costimulatory molecule
in lipopolysaccharide-induced acute lung injury. Journal of
Biomedicine and Biotechnology 2008: 852571.
- Esteva FJ, Wang J, Lin F, Mejia JA, Yan K et al. (2007). CD40
signaling predicts response to preoperative trastuzumab and
concomitant paclitaxel followed by 5-fluorouracil, epirubicin,
and cyclophosphamide in HER-2-overexpressing breast
cancer. Breast Cancer Research 9: R87.
- Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C et
al. (2009). Antitumor activity of an oncolytic adenoviral-CD40
ligand (CD154) transgene construct in human breast cancer
cells. Clinical Cancer Research 15: 1317-1325.
- Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J et al. (2010).
An online survival analysis tool to rapidly assess the effect of
22,277 genes on breast cancer prognosis using microarray data
of 1,809 patients. Breast Cancer Research and Treatment 123:
725-731.
- Kim H, Kim Y, Bae S, Kong JM, Choi J et al. (2015). Direct ınteraction
of CD40 on tumor cells with CD40L on T cells ıncreases the
proliferation of tumor cells by enhancing TGF-beta production
and Th17 differentiation. PLoS One 10: e0125742.
- Li R, Chen WC, Pang XQ, Hua C, Li L et al. (2009). Expression of
CD40 and CD40L in gastric cancer tissue and its clinical
significance. International Journal of Molecular Sciences 10:
3900-3917.
- Loskog AS, Eliopoulos AG (2009). The Janus faces of CD40 in cancer.
Seminars in Immunology 21: 301-307.
- Makhoul I, Atiq M, Alwbari A, Kieber-Emmons T (2018). Breast
cancer immunotherapy: an update. Breast Cancer: Basic and
Clinical Research 12. doi: 10.1177/1178223418774802
- Matsumura Y, Hiraoka K, Ishikawa K, Shoji Y, Noji T et al. (2016).
CD40 Expression in human esophageal squamous cell
carcinoma ıs associated with tumor progression and lymph
node metastasis. Anticancer Research 36: 4467-4475.
- Mu CY, Qin PX, Qu QX, Chen C, Huang JA (2015). Soluble CD40 in
plasma and malignant pleural effusion with non-small cell lung
cancer: A potential marker of prognosis. Chronic Diseases and
Translational Medicine 1: 36-41.
- Ottaiano A, De Chiara A, Perrone F, Botti G, Fazioli F et al. (2004).
Prognostic value of CD40 in adult soft tissue sarcomas. Clinical
Cancer Research 10: 2824-2831.
- Pearson LL, Castle BE, Kehry MR (2001). CD40-mediated signaling
in monocytic cells: up-regulation of tumor necrosis factor
receptor-associated factor mRNAs and activation of mitogenactivated protein kinase signaling pathways. International
Immunology 13: 273-283.
- Piechutta M, Berghoff AS (2019). New emerging targets in cancer
immunotherapy: the role of Cluster of Differentiation 40
(CD40/TNFR5). ESMO Open 4: e000510.
- Qin H, Wilson CA, Lee SJ, Zhao X, Benveniste EN (2005). LPS
induces CD40 gene expression through the activation of NFkappaB and STAT-1alpha in macrophages and microglia.
Blood 106: 3114-3122.
- Rydstrom K, Linderoth J, Nyman H, Ehinger M, Joost P et al.
(2010). CD40 is a potential marker of favorable prognosis
in patients with diffuse large B-cell lymphoma treated with
immunochemotherapy. Leukemia&Lymphoma 51: 1643-1648.
- Slobodova Z, Ehrmann J, Krejci V, Zapletalova J, Melichar B (2011).
Analysis of CD40 expression in breast cancer and its relation
to clinicopathological characteristics. Neoplasma 58: 189-197.
- Tone M, Tone Y, Fairchild PJ, Wykes M, Waldmann H (2001).
Regulation of CD40 function by its isoforms generated through
alternative splicing. Proceedings of the National Academy of
Sciences of the United States of America 98: 1751-1756.
- Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G et al.
(2001). Growth-inhibitory effects of CD40 ligand (CD154) and
its endogenous expression in human breast cancer. Clinical
Cancer Research 7: 691-703.
- Tong AW, Stone MJ (2003). Prospects for CD40-directed
experimental therapy of human cancer. Cancer Gene Therapy
10: 1-13.
- Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL et al. (2009).
Successful immunotherapy with IL-2/anti-CD40 induces the
chemokine-mediated mitigation of an immunosuppressive
tumor microenvironment. Proceedings of the National
Academy of Sciences of the United States of America 106:
19455-19460.
- Weiss JM, Gregory Alvord W, Quinones OA, Stauffer JK, Wiltrout
RH (2014). CD40 expression in renal cell carcinoma is
associated with tumor apoptosis, CD8(+) T cell frequency and
patient survival. Human Immunology 75: 614-620.
- Werner JM, Kuhl S, Ulrich K, Krischek B, Stavrinou P et al. (2019).
Expression of CD40 correlates negatively with overall and
progression-free survival of low- and high-grade gliomas.
World Neurosurgery 130: e17-e25.
- Wu W, Alexis NE, Bromberg PA, Jaspers I, Peden DB (2009).
Mechanisms of LPS-induced CD40 expression in human
peripheral blood monocytic cells. Biochemical and Biophysical
Research Communications 379: 573-577.
- Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW (1998). CD40
and epithelial cells: across the great divide. Immunology Today
19: 502-506.
- Yu S, Kim T, Yoo KH, Kang K (2017). The T47D cell line is an ideal
experimental model to elucidate the progesterone-specific
effects of a luminal A subtype of breast cancer. Biochemical
Biophysical Research Communications 486: 752-758.